{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T03:22:01Z","timestamp":1779160921051,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.suronc.2020.01.007","type":"journal-article","created":{"date-parts":[[2020,1,11]],"date-time":"2020-01-11T11:13:12Z","timestamp":1578741192000},"page":"74-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Is there an association between body mass index and 21-gene recurrence score?"],"prefix":"10.1016","volume":"34","author":[{"given":"Maria","family":"Pomponio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Burkbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macy","family":"Goldbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Keele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly C.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun R.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna M.","family":"Nazarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Tchou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.suronc.2020.01.007_bib1","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","author":"Paik","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.suronc.2020.01.007_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nrclinonc.2017.74","article-title":"Clinical utility of gene-expression signatures in early stage breast cancer","volume":"14","author":"Kwa","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2020.01.007_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.suronc.2020.01.007_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/IJWH.S124520","article-title":"Spotlight on the utility of the oncotype DX\u00ae breast cancer assay","volume":"10","author":"Siow","year":"2018","journal-title":"Int J Womens Health"},{"issue":"21","key":"10.1016\/j.suronc.2020.01.007_bib5","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.suronc.2020.01.007_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.suronc.2020.01.007_bib7","first-page":"393","volume":"vol 9","author":"McVeigh","year":"2017"},{"issue":"11","key":"10.1016\/j.suronc.2020.01.007_bib8","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.suronc.2020.01.007_bib9","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.2015.63.5383","article-title":"West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment","volume":"34","author":"Gluz","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.suronc.2020.01.007_bib10","first-page":"2","article-title":"The prognostic significance of the oncotype DX recurrence score in T1-2N1M0 estrogen receptor-positive HER2-negative breast cancer based on the prognostic stage in the updated AJCC 8th edition","author":"Wang","year":"2018","journal-title":"Ann. Surg. Oncol."},{"issue":"23","key":"10.1016\/j.suronc.2020.01.007_bib11","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.suronc.2020.01.007_bib12","series-title":"AJCC Cancer Staging Manual","author":"Hortobagyi","year":"2017"},{"issue":"5","key":"10.1016\/j.suronc.2020.01.007_bib13","first-page":"378","article-title":"Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention","volume":"67","author":"Picon-Ruiz","year":"2017","journal-title":"CA A Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.suronc.2020.01.007_bib14","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.suronc.2020.01.007_bib15","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1002\/cncr.27527","article-title":"Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer","volume":"118","author":"Sparano","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.suronc.2020.01.007_bib16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10549-012-2073-x","article-title":"Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis","volume":"134","author":"Niraula","year":"2012","journal-title":"Breast Canc. Res. Treat."},{"issue":"17","key":"10.1016\/j.suronc.2020.01.007_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults","volume":"348","author":"Calle","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.suronc.2020.01.007_bib18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/modpathol.2011.194","article-title":"A mitotically active, cellular tumor stroma and\/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas","volume":"25","author":"Acs","year":"2012","journal-title":"Mod. Pathol."},{"issue":"11","key":"10.1016\/j.suronc.2020.01.007_bib19","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/modpathol.2013.88","article-title":"Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas","volume":"26","author":"Acs","year":"2013","journal-title":"Mod. Pathol."},{"issue":"27_suppl","key":"10.1016\/j.suronc.2020.01.007_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1200\/jco.2011.29.27_suppl.171","article-title":"Is obesity associated with increased recurrence risk in estrogen receptor (ER)-positive breast cancer?","volume":"29","author":"Yap","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.suronc.2020.01.007_bib21","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-016-3846-4","article-title":"Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay","author":"Muniz","year":"2016","journal-title":"Breast Canc. Res. Treat."},{"issue":"15_suppl","key":"10.1016\/j.suronc.2020.01.007_bib22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/jco.2012.30.15_suppl.582","article-title":"Relationship between body mass index (BMI) at diagnosis of ER+ node negative breast cancer (BC) and Oncotype DX recurrence score","volume":"30","author":"Lohrisch","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"4 Supplement","key":"10.1016\/j.suronc.2020.01.007_bib23","article-title":"The effect of obesity and metabolic factors on genomic assays for risk of recurrence","volume":"78","author":"Soliman","year":"2018","journal-title":"Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.suronc.2020.01.007_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/jco.2012.30.15_suppl.555","article-title":"Obesity at diagnosis and breast cancer (BC) recurrence risk based on the 21-gene assay recurrence score (RS)","volume":"30","author":"Ridolfi","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2020.01.007_bib25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jeconom.2007.02.002","article-title":"Inverse probability weighted estimation for general missing data problems","volume":"141","author":"Wooldridge","year":"2007","journal-title":"J. Econom."},{"issue":"3","key":"10.1016\/j.suronc.2020.01.007_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"issue":"28","key":"10.1016\/j.suronc.2020.01.007_bib27","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med."},{"issue":"6","key":"10.1016\/j.suronc.2020.01.007_bib28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am. J. Epidemiol."},{"issue":"suppl_5","key":"10.1016\/j.suronc.2020.01.007_bib29","first-page":"2017","article-title":"Oncotype DX score, menopausal status and body mass index","volume":"28","author":"Picardo","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.suronc.2020.01.007_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6823-14-9","article-title":"The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies","volume":"14","author":"van Vliet-Ostaptchouk","year":"2014","journal-title":"BMC Endocr. Disord."},{"issue":"24 Supplement","key":"10.1016\/j.suronc.2020.01.007_bib31","article-title":"Metabolic syndrome and recurrence within the 21-gene recurrence score assay risk categories in lymph node negative breast cancer","volume":"72","author":"Lakhani","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.suronc.2020.01.007_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nyas.12416","article-title":"Obesity and cancer pathogenesis","volume":"1311","author":"Berger","year":"2014","journal-title":"Anna N Y Acad Sci"},{"key":"10.1016\/j.suronc.2020.01.007_bib33","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1634\/theoncologist.2012-0169","article-title":"The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer","volume":"17","author":"Del Fabbro","year":"2012","journal-title":"The Oncologist"}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740419303883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740419303883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:17:25Z","timestamp":1760757445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740419303883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":33,"alternative-id":["S0960740419303883"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2020.01.007","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is there an association between body mass index and 21-gene recurrence score?","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2020.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}